Physician profile
Charna Coren
NPI 1922334093
$2,587.78
in general payments reported to CMS, 2019-2025
27 companies · $834 in 2025
The $834 reported for 2025 was more than what 89% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $561 · 2020: $116 · 2021: $16.42 · 2022: $64.03 · 2023: $459 · 2024: $537 · 2025: $834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,829.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $336.97 | 2023-2025 | Accrufer |
| Abbvie INC. | $295.28 | 2019-2023 | Lo Loestrin Fe, Liletta, Ubrelvy |
| Astellas Pharma US INC | $276.69 | 2023-2025 | Veozah |
| Sumitomo Pharma America, INC. | $233.72 | 2023-2025 | Myfembree, Gemtesa |
| Sage Therapeutics, LLC | $198.77 | 2024-2025 | Zurzuvae |
| Exeltis, USA INC. | $174.44 | 2023-2025 | Slynd |
| Mayne Pharma Commercial LLC | $161.55 | 2023-2025 | |
| Therapeuticsmd, INC. | $136.62 | 2019-2022 | |
| Coopersurgical, INC. | $103.95 | 2019-2025 | Paragard T 380a |
| Bayer Healthcare Pharmaceuticals INC. | $89.29 | 2019-2023 | |
| Hologic Sales and Service, LLC | $86.91 | 2019-2025 | Thinprep 2000 Processor, Aptima, Fluent Fluid Management System |
| Mylan Pharmaceuticals INC. | $58.28 | 2019-2022 | |
| Avion Pharmaceuticals | $49.61 | 2019-2023 | Balcoltra |
| Millicent US INC | $45.89 | 2025 | Intrarosa, Femlyv |
| Daiichi Sankyo INC. | $45.63 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Meditrina | $37.22 | 2021-2025 | |
| Lupin INC. | $34.51 | 2019-2020 | |
| Pfizer INC. | $33.24 | 2023 | |
| Allergan, INC. | $29.23 | 2019 | |
| Lilly USA, LLC | $27.62 | 2019 | |
| Medtronic, INC. | $24.61 | 2023 | Truclear |
| Supernus Pharmaceuticals, INC. | $24.38 | 2025 | Qelbree |
| Covidien LP | $18.63 | 2019 | |
| Duchesnay USA Incorporated | $17.80 | 2019 | |
| Amgen INC. | $17.49 | 2025 | Prolia, Evenity |
| Vertical Pharmaceuticals, LLC | $15.89 | 2019 | |
| Novo Nordisk INC | $13.56 | 2023 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charna Coren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.